NWL
32
-3
FAST
46
-2
HUM
30
3
PWR
60
-2
FTI
69
-7
CNX
76
5
SWK
80
2
HPE
53
2
LH
55
2
ITW
62
-2
HRB
70
-3
GRMN
50
-2
CMCSA
52
6
NTAP
58
2
AEP
59
-3
NUE
50
3
GOOG
63
2
M
14
2
STX
53
-4
TSCO
55
-2
NWL
32
-3
FAST
46
-2
HUM
30
3
PWR
60
-2
FTI
69
-7
CNX
76
5
SWK
80
2
HPE
53
2
LH
55
2
ITW
62
-2
HRB
70
-3
GRMN
50
-2
CMCSA
52
6
NTAP
58
2
AEP
59
-3
NUE
50
3
GOOG
63
2
M
14
2
STX
53
-4
TSCO
55
-2
Financhill
Back

Heron Therapeutics 10K Form

Sell
18

HRTX
Heron Therapeutics

Last Price:
2.05
Seasonality Move:
-7.28%

7 Day Trial

ALL ACCESS PASS

$ 7

Key Filings

10K form not available

Receive HRTX News And Ratings

See the #1 stock for the next 7 days that we like better than HRTX

HRTX Financial Statistics

Sales & Book Value

Annual Sales: $127.04M
Cash Flow: $-5.24M
Price / Cash Flow: 0
Annual Sales: $-0.25
Price / Book: 0

Profitability

EPS (TTM): -0.30000
Net Income (TTM): $-48.13M
Gross Margin: $61.94M
Return on Equity: 0%
Return on Assets: -22.1%

Heron Therapeutics Earnings Forecast

Key Heron Therapeutics Financial Ratios

  • The Gross Profit Margin over the past 37 years for HRTX is 48.75%.
  • The Selling, General & Administrative Expenses for HRTX have been equal to 91.82% of Gross Profit Margin.
  • The Research & Development expenses have been 44.00% of Revenue.
  • The Interest Expense is -3.50% of Operating Income.
  • The Net Earning history of HRTX is -87.02% of Total Revenues.
  • Per Share Earnings over the last 37 years have been positive in 20 years.

Heron Therapeutics Stock Price Chart

Industry, Sector and Symbol

Stock Exchange: NASDAQ
Industry: Biotechnology
Sector: Health Care
Current Symbol: HRTX
CUSIP: 427746
Website: herontx.com

Debt

Debt-to-Equity Ratio: -4.59
Current Ratio: 2.38
Quick Ratio: 1.76

Price-to-Earnings

Trailing P/E Ratio: 0
Forward P/E Ratio: 0

HRTX Technical Analysis vs Fundamental Analysis

Sell
18
Heron Therapeutics (HRTX) is a Sell

Is Heron Therapeutics a Buy or a Sell?